Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

Clinical and Laboratory Standards Institute

Gressner, A. M., & Arndt, T. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,092 · see citing works

Infectious Diseases Society of America

Enders, J. F. (1969) · The Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,305 · see citing works

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America

Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works

Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections

Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · see citing works

Medically Important Fungi: A Guide to Identification

Larone, D. H. (1976) · Cited by 809 · see citing works

Infections Caused by <i>Scedosporium</i> spp

Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786 · see citing works

Manual of Clinical Microbiology

Schaeffer, M. (1971) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1971.20.3.tm0200030508a · Cited by 767 · see citing works

Frequency and Evolution of Azole Resistance in <i>Aspergillus fumigatus</i> Associated with Treatment Failure1

Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750 · see citing works

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., Dupont, B., Torre‐Cisneros, J., Just‐Nübling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 672 · see citing works

Medically important fungi: A guide to identification

Ajello, L. (1989) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(89)90040-0 · Cited by 667 · see citing works

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

Parczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656 · see citing works

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

Rodríguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca‐Estrella, M., Dannaoui, É., Denning, D. W., Donnelly, J. P., Dromer, F., et al. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01935.x · Cited by 651 · see citing works

Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases

van Burik, J. H., Hare, R. S., Solomon, H. F., Corrado, M. L., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/500212 · Cited by 614 · see citing works

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484 · see citing works

Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007–2009

van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging infectious diseases · doi:10.3201/eid1710.110226 · Cited by 445 · see citing works

Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444 · see citing works

Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008

Pfaller, M. A., Neofytos, D., Diekema, D. J., Azie, N. E., Meier‐Kriesche, H., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 391 · see citing works

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata

Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377 · see citing works

Epidemiology of invasive candidiasis

Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376 · see citing works

Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3623-3626.2003 · Cited by 370 · see citing works

Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011.

Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366 · see citing works

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

Pfaller, M. A., Diekema, D. J., Andes, D. R., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. R., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 335 · see citing works

Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009

Bueid, A. S., Howard, S. J., Moore, C. B., Richardson, M. D., Harrison, E., Bowyer, P., & Denning, D. W. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq279 · Cited by 333 · see citing works

Sequence-Based Identification of Aspergillus, Fusarium , and Mucorales Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here?

Balajee, S. A., Borman, A. M., Brandt, M. E., Cano, J., Cuenca‐Estrella, M., Dannaoui, É., Guarro, J., Haase, G., Kibbler, C. C., Meyer, W., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01685-08 · Cited by 326 · see citing works

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314 · see citing works

Identification of Medically Important Yeast Species by Sequence Analysis of the Internal Transcribed Spacer Regions

Leaw, S. N., Chang, H. C., Sun, H. S., Barton, R., Bouchara, J.-P., & Chang, T. C. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.693-699.2006 · Cited by 308 · see citing works

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

RAAD, I. I., Hachem, R. Y., Herbrecht, R., Graybill, J. R., Hare, R. S., Corcoran, G., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503425 · Cited by 299 · see citing works

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

Espinel-Ingroff, A. V., Diekema, D. J., Fothergill, A. W., Johnson, E. M., Peláez, T., Pfaller, M. A., Rinaldi, M. G., Cantón, R., & Turnidge, J. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00536-10 · Cited by 240 · see citing works

Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections

Parkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm212 · Cited by 229 · see citing works

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01398-10 · Cited by 228 · see citing works

Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods

Alastruey‐Izquierdo, A., Cuenca‐Estrella, M., Monzón, A., Mellado, E., & Rodríguez-Tudela, J. L. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn022 · Cited by 222 · see citing works

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012

Azie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222 · see citing works

Pseudallescheria boydii Brain Abscess Successfully Treated with Voriconazole and Surgical Drainage: Case Report and Literature Review of Central Nervous System Pseudallescheriasis

Nesky, M. A., McDougal, E. C., & Peacock, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/314042 · Cited by 214 · see citing works

Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus

Rodrı́guez-Tudela, J. L., Alcázar‐Fuoli, L., Mellado, E., Alastruey‐Izquierdo, A., Monzón, A., & Cuenca‐Estrella, M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00156-08 · Cited by 209 · see citing works

Acquired antifungal drug resistance inAspergillus fumigatus:epidemiology and detection

Howard, S. J., & Arendrup, M. C. (2010) · Medical Mycology · doi:10.3109/13693786.2010.508469 · Cited by 199 · see citing works

Breakthrough invasive candidiasis in patients on micafungin.

Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196 · see citing works

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Balajee, S. A., Pappas, P. G., & Moser, S. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00854-09 · Cited by 190 · see citing works

Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey

Pemán, J., Cantón, R., Quindós, G., Eraso, E., Alcoba-Flórez, J., Guinea, J., Merino, P., Ruiz-Pérez-de-Pipaon, M. T., del Molino, L. P., Linares-Sicilia, M. J., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks019 · Cited by 159 · see citing works

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp

Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., Jones, R. N., Turnidge, J. D., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01590-09 · Cited by 154 · see citing works

Contemporary tools for the diagnosis and management of invasive mycoses

Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147 · see citing works

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine

Espinel‐Ingroff, A., Chowdhary, A., Cuenca‐Estrella, M., Fothergill, A., Fuller, J., Hagen, F., Govender, N. P., Guarro, J., Johnson, E. M., Lass‐Flörl, C., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06252-11 · Cited by 145 · see citing works

Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy

Magill, S. S., Shields, C. E., Sears, C. L., Choti, M. A., & Merz, W. G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.529-535.2006 · Cited by 137 · see citing works

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria

Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130 · see citing works

Low Prevalence of <i>fks1</i> Hot Spot 1 Mutations in a Worldwide Collection of <i>Candida</i> Strains

Castanheira, M., Woosley, L. N., Diekema, D. J., Messer, S. A., Jones, R. N., & Pfaller, M. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01711-09 · Cited by 125 · see citing works

Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies

Alanio, A., Sitterlé, E., Liance, M., Farrugia, C., Foulet, F., Botterel, F., Hicheri, Y., Cordonnier, C., Costa, J., & Bretagne, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq450 · Cited by 122 · see citing works

Treatment ofScedosporium apiospermumBrain Abscesses with Posaconazole

Mellinghoff, I. K., Winston, D. J., Mukwaya, G., & Schiller, G. J. (2002) · Clinical Infectious Diseases · doi:10.1086/340522 · Cited by 121 · see citing works

Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)

Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.08.013 · Cited by 119 · see citing works

Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes

Grim, S. A., Berger, K., Teng, C. B., Gupta, S., Layden, J. E., Janda, W. M., & Clark, N. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr511 · Cited by 119 · see citing works

Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without <i>FKS</i> Resistance Mutations

Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117 · see citing works

Molecular Identification of Unusual Pathogenic Yeast Isolates by Large Ribosomal Subunit Gene Sequencing: 2 Years of Experience at the United Kingdom Mycology Reference Laboratory

Linton, C. J., Borman, A. M., Cheung, G. C. N., Holmes, A. D., Székely, A., Palmer, M. D., Bridge, P. D., Campbell, C. K., & Johnson, E. M. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02061-06 · Cited by 111 · see citing works

Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs

Castanheira, M., Woosley, L. N., Diekema, D. J., Jones, R. N., & Pfaller, M. A. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01686-12 · Cited by 100 · see citing works

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

Pfaller, M. A., Woosley, L. N., Messer, S. A., Jones, R. N., & Castanheira, M. (2012) · Mycopathologia · doi:10.1007/s11046-012-9551-x · Cited by 84 · see citing works

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species

Arendrup, M. C., Kahlmeter, G., Rodrı́guez-Tudela, J. L., & Donnelly, J. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-08 · Cited by 62 · see citing works

Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program

Pfaller, M. A., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01952-07 · Cited by 55 · see citing works

Initial results from a longitudinal international surveillance programme for anidulafungin (2003)

Messer, S. A., Kirby, J. T., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh504 · Cited by 52 · see citing works

Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients

Hadley, S. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.415 · Cited by 29 · see citing works

Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia

Baddley, J. W., Patel, M., Jones, M., Cloud, G. A., Smith, A. C., & Moser, S. A. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.004 · Cited by 28 · see citing works

Current issues in the clinical management of invasive aspergillosis – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009

Rüping, M. J. G. T., Vehreschild, J. J., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Cornely, O. A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01989.x · Cited by 24 · see citing works

Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009

Karthaus, M., Rüping, M. J. G. T., Cornely, O. A., Steinbach, A., Groll, A. H., Lass‐Flörl, C., Ostermann, H., Ruhnke, M., & Vehreschild, J. J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01988.x · Cited by 13 · see citing works

In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Perkhofer, S., Mrazek, C., Hartl, L., & Lass‐Flörl, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0134-z · Cited by 12 · see citing works

Does One Voriconazole Breakpoint Suit All Candida Species?

Arendrup, M. C., & Denning, D. W. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00412-07 · Cited by 9 · see citing works

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556 · see citing works

The global problem of antifungal resistance: prevalence, mechanisms, and management

Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055 · see citing works

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species

Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900 · see citing works

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825 · see citing works

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101510 · Cited by 396 · see citing works

Antifungal drug resistance among <i>Candida</i> species: mechanisms and clinical impact

Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394 · see citing works

Echinocandin resistance in Candida.

Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374 · see citing works

Mechanisms of echinocandin antifungal drug resistance

Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313 · see citing works

Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance

Cleveland, A. A., Harrison, L. H., Farley, M. M., Hollick, R., Stein, B., Chiller, T. M., Lockhart, S. R., & Park, B. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120452 · Cited by 304 · see citing works

Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens

Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230 · see citing works

Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults

Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · see citing works

Changing epidemiology of candidaemia in Australia

Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw422 · Cited by 163 · see citing works

Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values

Pfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.04.008 · Cited by 127 · see citing works

Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and <i>In Vivo</i> Impact in Infected Galleria mellonella Larvae

Souza, A. C. R., Fuchs, B. B., Pinhati, H. M. S., Siqueira, R. A., Hagen, F., Meis, J. F., Mylonakis, E., & Colombo, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01177-15 · Cited by 121 · see citing works

Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model

Zhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102 · see citing works

Current Epidemiology of Candida Infection

Lockhart, S. R. (2014) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2014.08.001 · Cited by 101 · see citing works

Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99 · see citing works

Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species

Fothergill, A. W., Sutton, D. A., McCarthy, D. I., & Wiederhold, N. P. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03044-13 · Cited by 96 · see citing works

Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species

Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84 · see citing works

CD101: a novel long-acting echinocandin

Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81 · see citing works

Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria

Pfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74 · see citing works

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)

Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68 · see citing works

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies

Rivero-Menendez, O., Cuenca-Estrella, M., & Alastruey-Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz078 · Cited by 66 · see citing works

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species

Pfaller, M. A., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.008 · Cited by 67 · see citing works

Positions and Numbers of <i>FKS</i> Mutations in Candida albicans Selectively Influence <i>In Vitro</i> and <i>In Vivo</i> Susceptibilities to Echinocandin Treatment

Lackner, M., Tscherner, M., Schaller, M., Kuchler, K., Mair, C., Sartori, B., Istel, F., Arendrup, M. C., & Lass-Flörl, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00123-14 · Cited by 67 · see citing works

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections

Castanheira, M., Messer, S. A., Jones, R. N., Farrell, D. J., & Pfaller, M. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.007 · Cited by 66 · see citing works

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012)

Pfaller, M. A., Messer, S. A., Jones, R. N., & Castanheira, M. (2015) · The Journal of Antibiotics · doi:10.1038/ja.2015.29 · Cited by 64 · see citing works

Decreased echinocandin susceptibility in <i>Candida parapsilosis</i> causing candidemia and emergence of a pan-echinocandin resistant case in China

Ning, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., et al. (2023) · Emerging Microbes &amp; Infections · doi:10.1080/22221751.2022.2153086 · Cited by 63 · see citing works

<i>UPC2A</i> Is Required for High-Level Azole Antifungal Resistance in Candida glabrata

Whaley, S. G., Caudle, K. E., Vermitsky, J.-P., Chadwick, S. G., Toner, G., Barker, K. S., Gygax, S. E., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02217-13 · Cited by 52 · see citing works

Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria

Pfaller, M. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00782-14 · Cited by 51 · see citing works

Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center.

Marcos-Zambrano, L. J., Escribano, P., Sánchez, C., Muñoz, P., Bouza, E., & Guinea, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02670-14 · Cited by 49 · see citing works

A Transcriptomics Approach To Unveiling the Mechanisms of <i>In Vitro</i> Evolution towards Fluconazole Resistance of a <i>Candida glabrata</i> Clinical Isolate

Cavalheiro, M., Costa, C., Silva-Dias, A., Miranda, I. M., Wang, C., Pais, P., Pinto, S. N., Mil-Homens, D., Sato-Okamoto, M., Takahashi-Nakaguchi, A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-18 · Cited by 42 · see citing works

Comparative genomic and transcriptomic analyses unveil novel features of azole resistance and adaptation to the human host in Candida glabrata

Salazar, S. B., Wang, C., Münsterkötter, M., Okamoto, M., Takahashi-Nakaguchi, A., Chibana, H., Lopes, M. M., Güldener, U., Butler, G., & Mira, N. P. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/fox079 · Cited by 31 · see citing works

The role of aneuploidy in the emergence of echinocandin resistance in human fungal pathogen Candida albicans

Sah, S. K., Hayes, J. J., & Rustchenko, E. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009564 · Cited by 26 · see citing works

Candida albicans Strains Adapted to Caspofungin Due to Aneuploidy Become Highly Tolerant under Continued Drug Pressure

Husain, F., Yadav, A., Sah, S. K., Hayes, J. J., & Rustchenko, E. (2022) · Microorganisms · doi:10.3390/microorganisms11010023 · Cited by 10 · see citing works

Whole Genome Analysis of Echinocandin Non‐Susceptible Candida Glabrata Clinical Isolates: a Multi‐Center Study in China

Li, Y., Hou, X., Li, R., Liao, K., Ma, L., Wang, X., Ji, P., Kong, H., Xia, Y., Ding, H., et al. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03105-3 · Cited by 7 · see citing works

Multidrug-resistant Candida glabrata strains obtained by induction of anidulafungin resistance in planktonic and biofilm cells

Hatwig, C., Balbueno, E. A., Bergamo, V. Z., Pippi, B., Fuentefria, A. M., & Silveira, G. P. (2019) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902019000218025 · Cited by 6 · see citing works

Fungal infections today: size of the problem and focus on the initial cost of therapy with echinocandin

Venditti, M. (2010) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v11i2.181

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Tóth, Z., Forgács, L., Kardos, T., Kovács, R., Locke, J. B., Kardos, G., Nagy, F., Borman, A. M., Adnan, A., & Majoros, L. (2020) · Journal of Fungi · doi:10.3390/jof6030136 · Cited by 20 · see citing works

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata

Spreghini, E., Orlando, F., Sanguinetti, M., Posteraro, B., Giannini, D., Manso, E., & Barchiesi, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05872-11 · Cited by 37 · see citing works

In Vitro Echinocandin Susceptibility of Aspergillus Isolates from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

Lockhart, S. R., Zimbeck, A. J., Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Pappas, P. G., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00428-11 · Cited by 38 · see citing works

A Clinical Review of Echinocandins in Pediatric Patients

VandenBussche, H. L., & Loo, D. A. V. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m139 · Cited by 39 · see citing works